116 related articles for article (PubMed ID: 7954404)
1. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
He J; Allen JR; Collins VP; Allalunis-Turner MJ; Godbout R; Day RS; James CD
Cancer Res; 1994 Nov; 54(22):5804-7. PubMed ID: 7954404
[TBL] [Abstract][Full Text] [Related]
2. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
3. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.
He J; Olson JJ; James CD
Cancer Res; 1995 Nov; 55(21):4833-6. PubMed ID: 7585516
[TBL] [Abstract][Full Text] [Related]
4. Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
Srivenugopal KS; Ali-Osman F
Oncogene; 1996 May; 12(9):2029-34. PubMed ID: 8649864
[TBL] [Abstract][Full Text] [Related]
5. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
6. Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ
Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764
[TBL] [Abstract][Full Text] [Related]
7. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Zariwala M; Liu E; Xiong Y
Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
10. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
[TBL] [Abstract][Full Text] [Related]
11. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines.
Kees UR; Ranford PR; Hatzis M
Oncogene; 1996 May; 12(10):2235-9. PubMed ID: 8668350
[TBL] [Abstract][Full Text] [Related]
12. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines.
Igaki H; Sasaki H; Kishi T; Sakamoto H; Tachimori Y; Kato H; Watanabe H; Sugimura T; Terada M
Biochem Biophys Res Commun; 1994 Sep; 203(2):1090-5. PubMed ID: 8093026
[TBL] [Abstract][Full Text] [Related]
13. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
Zheng J; Hou P; Zhou C
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
[TBL] [Abstract][Full Text] [Related]
14. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Zariwala M; Xiong Y
Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
[TBL] [Abstract][Full Text] [Related]
15. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.
Tenan M; Benedetti S; Finocchiaro G
Biochem Biophys Res Commun; 1995 Dec; 217(1):195-202. PubMed ID: 8526910
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
17. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
18. Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation.
Hama S; Sadatomo T; Yoshioka H; Kurisu K; Tahara E; Naruse I; Heike Y; Saijo N
Anticancer Res; 1997; 17(3C):1933-8. PubMed ID: 9216647
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Schutte M; Hruban RH; Geradts J; Maynard R; Hilgers W; Rabindran SK; Moskaluk CA; Hahn SA; Schwarte-Waldhoff I; Schmiegel W; Baylin SB; Kern SE; Herman JG
Cancer Res; 1997 Aug; 57(15):3126-30. PubMed ID: 9242437
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
